Equities research analysts expect Boston Scientific (NYSE:BSX) to announce earnings per share of $0.31 for the current quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Boston Scientific’s earnings, with the lowest EPS estimate coming in at $0.31 and the highest estimate coming in at $0.33. Boston Scientific posted earnings of $0.29 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.9%. The business is scheduled to report its next quarterly earnings results before the market opens on Wednesday, April 25th.

On average, analysts expect that Boston Scientific will report full-year earnings of $1.37 per share for the current financial year, with EPS estimates ranging from $1.35 to $1.39. For the next year, analysts anticipate that the company will report earnings of $1.54 per share, with EPS estimates ranging from $1.52 to $1.58. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Boston Scientific.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.34. The business had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.30 EPS.

A number of research analysts have recently weighed in on BSX shares. Zacks Investment Research raised Boston Scientific from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Bank of America lifted their price objective on Boston Scientific from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, April 5th. Barclays reaffirmed a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research report on Wednesday, January 10th. Morgan Stanley lifted their price objective on Boston Scientific from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Monday, March 19th. Finally, TheStreet raised Boston Scientific from a “c+” rating to a “b” rating in a research report on Thursday, January 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $31.45.

Boston Scientific stock opened at $28.84 on Thursday. The stock has a market cap of $39,652.43, a price-to-earnings ratio of 22.89, a PEG ratio of 2.09 and a beta of 0.81. Boston Scientific has a 52-week low of $24.54 and a 52-week high of $29.93. The company has a quick ratio of 0.49, a current ratio of 0.68 and a debt-to-equity ratio of 0.54.

In related news, EVP Kevin J. Ballinger sold 42,803 shares of the business’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $28.32, for a total value of $1,212,180.96. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP David A. Pierce sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $27.22, for a total value of $136,100.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 238,903 shares of company stock worth $6,497,699. 0.73% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of BSX. Arrowstreet Capital Limited Partnership lifted its holdings in Boston Scientific by 371.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 7,149,847 shares of the medical equipment provider’s stock worth $177,245,000 after purchasing an additional 5,633,721 shares in the last quarter. Prudential Financial Inc. raised its holdings in shares of Boston Scientific by 149.1% during the 3rd quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock worth $138,928,000 after acquiring an additional 2,850,630 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Boston Scientific by 59.0% during the 4th quarter. Two Sigma Advisers LP now owns 7,426,814 shares of the medical equipment provider’s stock worth $184,111,000 after acquiring an additional 2,756,504 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Boston Scientific by 29.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,945,671 shares of the medical equipment provider’s stock worth $296,133,000 after acquiring an additional 2,705,194 shares in the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of Boston Scientific by 79.2% during the 4th quarter. Two Sigma Investments LP now owns 3,702,539 shares of the medical equipment provider’s stock worth $91,786,000 after acquiring an additional 1,635,881 shares in the last quarter. 91.05% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/04/22/boston-scientific-bsx-expected-to-announce-earnings-of-0-31-per-share.html.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Get a free copy of the Zacks research report on Boston Scientific (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.